The SEA CHANGE Study: A Self Management Intervention for Head and Neck Cancer Survivors

NCT ID: NCT04051697

Last Updated: 2019-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-10

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to test the feasibility of implementing the Self-Management after Cancer of the Head and Neck Group Intervention (SEA-CHANGE), designed to promote quality of life and participation in life activities and reduce distress in people who have completed primary treatment for head and neck cancer as compared to usual care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Head and neck cancer (HNC) and its treatment are associated with specific challenges such as facial disfigurement and impairments in speech, breathing and swallowing, and can have a negative impact on well-being. Self-management interventions can provide people with skills to deal with health-related problems, maintain life roles, and manage negative emotions, and have been found to increase confidence, improve quality of life, and reduce health service use across a range of chronic conditions.

The aim of this study is to pilot a self-management intervention (SEA-CHANGE) designed to promote quality of life and participation in life activities, and reduce distress in people who have completed primary treatment for HNC as compared to usual care. The study includes: (1) a pilot randomised study to assess the feasibility and acceptability of the intervention and its related procedures; (2) a qualitative process evaluation of the intervention; and (3) a systematic decision-making process regarding progression to a definitive trial. The expected outcome is a self-management intervention that is feasible and acceptable to HNC survivors and has the potential to realise both health benefits and economic gains.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two-armed (intervention vs usual care) non-blinded pilot randomised control trial
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care arm

Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention arm

Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.

Group Type EXPERIMENTAL

SEA CHANGE intervention

Intervention Type BEHAVIORAL

The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SEA CHANGE intervention

The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* had a pathologically confirmed diagnosis of an invasive primary tumour in the head and neck (oral cavity, salivary glands, nasal cavity, sinuses, middle ear, pharynx and larynx);
* have undergone and completed treatment by surgery, chemotherapy, radiotherapy or a combination thereof;
* are aged 18 or older at the time of their HNC diagnosis;
* are within 12 months of having completed their primary treatment; and
* have provided written informed, consent.

Exclusion Criteria

* are unable to read or speak English;
* had a second invasive primary cancer other than non-melanoma skin cancer diagnosed after the HNC (as these patients are likely to be more focused on the treatment of their second cancer rather than self-management of their HNC);
* are unable to provide informed consent (e.g., if they have dementia/Alzheimer's disease); or
* have other known medical condition or other reason why they would be unable to take part.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University of Ireland, Maynooth

OTHER

Sponsor Role collaborator

Newcastle University

OTHER

Sponsor Role collaborator

St. James's Hospital, Ireland

OTHER

Sponsor Role collaborator

St. Luke's Hospital

UNKNOWN

Sponsor Role collaborator

Royal Victoria Eye and Ear Hospital

OTHER_GOV

Sponsor Role collaborator

Dublin City University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pamela Gallagher, PhD

Prof Pamela Gallagher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pamela Gallagher, PhD

Role: PRINCIPAL_INVESTIGATOR

Dublin City University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Victoria Eye and Ear Hospital, Ireland

Dublin, , Ireland

Site Status RECRUITING

St James Hospital, Ireland

Dublin, , Ireland

Site Status RECRUITING

St Lukes Hospital, Ireland

Dublin, , Ireland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ireland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pamela Gallagher, PhD

Role: CONTACT

+353170058958

Nicholas Clarke, PhD

Role: CONTACT

+35317005317

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Prof Timon, MD

Role: primary

+35314162677

Prof Timon, MD

Role: primary

+35314162677

Sinead Brennan, MD

Role: primary

+35314065000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DIFA-2017-022

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

DIFA-2017-022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Depression and Adherence in Head and Neck Cancer
NCT00498875 ACTIVE_NOT_RECRUITING